246 related articles for article (PubMed ID: 30096791)
1. UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer.
Hardy LR; Salvi A; Burdette JE
Cancers (Basel); 2018 Aug; 10(8):. PubMed ID: 30096791
[TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
3. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.
Rodgers LH; Ó hAinmhire E; Young AN; Burdette JE
Oncotarget; 2016 May; 7(22):32785-95. PubMed ID: 27129161
[TBL] [Abstract][Full Text] [Related]
4. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of paired box genes 8 and 2 expression in epithelium tissues and the related tumors].
Song Y; Huang X; Shen GH; Liu XY; Zhang X
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):424-428. PubMed ID: 28635231
[No Abstract] [Full Text] [Related]
6. PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far.
Di Palma T; Zannini M
Onco Targets Ther; 2022; 15():1273-1280. PubMed ID: 36275185
[TBL] [Abstract][Full Text] [Related]
7. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
[TBL] [Abstract][Full Text] [Related]
8. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
[TBL] [Abstract][Full Text] [Related]
9. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
10. PAX8, an Emerging Player in Ovarian Cancer.
Gokulnath P; Soriano AA; de Cristofaro T; Di Palma T; Zannini M
Adv Exp Med Biol; 2021; 1330():95-112. PubMed ID: 34339032
[TBL] [Abstract][Full Text] [Related]
11. Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.
de Cristofaro T; Di Palma T; Soriano AA; Monticelli A; Affinito O; Cocozza S; Zannini M
Oncotarget; 2016 Jul; 7(27):41929-41947. PubMed ID: 27259239
[TBL] [Abstract][Full Text] [Related]
12. Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
[TBL] [Abstract][Full Text] [Related]
13. PAX8 modulates the tumor microenvironment of high grade serous ovarian cancer through changes in the secretome.
Salvi A; Hardy LR; Heath KN; Watry S; Pergande MR; Cologna SM; Burdette JE
Neoplasia; 2023 Feb; 36():100866. PubMed ID: 36586182
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
Hardy LR; Pergande MR; Esparza K; Heath KN; Önyüksel H; Cologna SM; Burdette JE
Oncogene; 2019 Aug; 38(32):6003-6016. PubMed ID: 31296958
[TBL] [Abstract][Full Text] [Related]
16. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
17. [Expansion of secretory cells in the fallopian tubal epithelium in the early stages of the pathogenesis of ovarian serous carcinomas].
Asaturova AV; Ezhova LS; Faizullina NM; Adamyan LV; Khabas GN; Sannikova MV
Arkh Patol; 2017; 79(3):10-18. PubMed ID: 28631711
[TBL] [Abstract][Full Text] [Related]
18. PAX8 expression in ovarian surface epithelial cells.
Adler E; Mhawech-Fauceglia P; Gayther SA; Lawrenson K
Hum Pathol; 2015 Jul; 46(7):948-56. PubMed ID: 26079312
[TBL] [Abstract][Full Text] [Related]
19. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
[TBL] [Abstract][Full Text] [Related]
20. Diffuse expression of PAX2 and PAX8 in the cystic epithelium of mixed epithelial stromal tumor, angiomyolipoma with epithelial cysts, and primary renal synovial sarcoma: evidence supporting renal tubular differentiation.
Karafin M; Parwani AV; Netto GJ; Illei PB; Epstein JI; Ladanyi M; Argani P
Am J Surg Pathol; 2011 Sep; 35(9):1264-73. PubMed ID: 21836481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]